McKesson Corporation $MCK Stake Boosted by Capital International Investors

Capital International Investors lifted its stake in shares of McKesson Corporation (NYSE:MCK) by 13.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 183,925 shares of the company’s stock after purchasing an additional 21,371 shares during the quarter. Capital International Investors owned about 0.15% of McKesson worth $142,089,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Obsidian Personal Planning Solutions LLC increased its position in McKesson by 2.9% in the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock worth $346,000 after buying an additional 12 shares during the period. IAM Advisory LLC boosted its holdings in shares of McKesson by 0.3% during the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock valued at $3,019,000 after acquiring an additional 13 shares during the period. PDS Planning Inc grew its position in shares of McKesson by 1.1% during the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after acquiring an additional 13 shares during the last quarter. Berkshire Asset Management LLC PA increased its holdings in shares of McKesson by 4.6% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after acquiring an additional 13 shares during the period. Finally, Goldstein Advisors LLC increased its holdings in shares of McKesson by 4.4% in the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock worth $258,000 after acquiring an additional 14 shares during the period. Institutional investors own 85.07% of the company’s stock.

Insider Activity

In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Maria Martinez sold 349 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the sale, the director owned 301 shares of the company’s stock, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,868 shares of company stock worth $3,743,820 in the last quarter. 0.08% of the stock is currently owned by corporate insiders.

McKesson Trading Up 0.6%

McKesson stock opened at $934.13 on Thursday. McKesson Corporation has a 52 week low of $635.00 and a 52 week high of $999.00. The stock has a market cap of $114.42 billion, a price-to-earnings ratio of 26.87, a PEG ratio of 1.49 and a beta of 0.38. The company’s 50-day moving average price is $889.07 and its two-hundred day moving average price is $821.67.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same period in the prior year, the business posted $8.03 EPS. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts expect that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Raymond James Financial set a $970.00 target price on shares of McKesson in a research note on Thursday, March 5th. TD Cowen raised their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Barclays boosted their price objective on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Robert W. Baird set a $968.00 price objective on McKesson in a report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. raised their target price on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $960.93.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.